Quantbot Technologies LP Has $947,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Quantbot Technologies LP increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 119,533 shares of the company’s stock after buying an additional 8,352 shares during the quarter. Quantbot Technologies LP’s holdings in Amneal Pharmaceuticals were worth $947,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AMRX. Franklin Resources Inc. increased its holdings in shares of Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after acquiring an additional 4,178 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Amneal Pharmaceuticals by 13.6% in the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock worth $320,000 after purchasing an additional 4,851 shares during the last quarter. Globeflex Capital L P raised its position in Amneal Pharmaceuticals by 3.8% in the 4th quarter. Globeflex Capital L P now owns 144,439 shares of the company’s stock valued at $1,144,000 after buying an additional 5,245 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock valued at $366,000 after acquiring an additional 5,523 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Amneal Pharmaceuticals by 1.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 555,655 shares of the company’s stock valued at $4,401,000 after acquiring an additional 6,680 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

AMRX has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.80.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $8.53 on Wednesday. The company has a market capitalization of $2.64 billion, a PE ratio of -12.54 and a beta of 1.05. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.18 and a 52-week high of $9.48. The company has a 50-day simple moving average of $8.41 and a 200 day simple moving average of $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same period last year, the firm posted $0.14 EPS. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Activity

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares of the company’s stock, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gautam Patel sold 17,410 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,240,000 shares of company stock valued at $43,754,000 in the last 90 days. Insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.